Gabrielle Cerda, MD
Psychiatry · San Diego, CANPI 1407887748
Payments from drug & device makers
Across 220 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$982
- Johnson & Johnson$827
- Otsuka America Pharmaceutical, Inc.$686
- Neurocrine Biosciences, Inc.$386
- Teva Pharmaceuticals USA, Inc.$385
- plus $506 from 4 others
What the payments were for
- Food & beverage$4,79299%
- Education$661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 60 | $1,084 |
| Alkermes, Inc. | 34 | $982 |
| Johnson & Johnson | 42 | $827 |
| Otsuka America Pharmaceutical, Inc. | 27 | $686 |
| Neurocrine Biosciences, Inc. | 17 | $386 |
| Teva Pharmaceuticals USA, Inc. | 19 | $385 |
| AbbVie | 9 | $217 |
| Indivior Inc. | 6 | $155 |
| Lundbeck LLC | 5 | $99 |
| Janssen Scientific Affairs, LLC | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$224
- INVEGA SUSTENNA$142
- ABILIFY MAINTENA$124
- ABILIFY ASIMTUFII$124
- REXULTI$122
- VIVITROL$119
How this compares
$4,857 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 85 | $264,592 |
| IngrezzaValbenazine Tosylate | 38 | $261,534 |
| AustedoDeutetrabenazine | 13 | $73,727 |
| CaplytaLumateperone Tosylate | 48 | $70,533 |
| Abilify MaintenaAripiprazole | 19 | $54,608 |
| VraylarCariprazine Hcl | 26 | $37,337 |
| AristadaAripiprazole Lauroxil | 16 | $37,266 |
| UzedyRisperidone | 17 | $36,382 |
| Risperdal ConstaRisperidone Microspheres | 11 | $12,873 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,606 |
| Lurasidone Hcl | 23 | $4,956 |
| Haloperidol Decanoate | 64 | $3,273 |
| Aripiprazole | 106 | $3,209 |
| Haloperidol | 85 | $2,571 |
| Clozapine | 33 | $2,489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $827 | $277,46596 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $386 | $261,53438 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy | $385 | $110,11030 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,084 | $70,53348 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $686 | $54,60819 claims |
| AbbVieVraylar | $217 | $37,33726 claims |
| Alkermes, Inc.Aristada | $982 | $37,26616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.
Other psychiatry in San Diego
- Eric ChavezSan Diego$15.5M
- Charmaine SemeniukSan Diego$8.9M
- Jonathan MeyerSan Diego$2.3M
- Vishaal MehraSan Diego$1M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.